tbuckley/cabot-search huggingface dataset:
In ischemic left ventricular systolic dysfunction, adding PCI to medical therapy did not reduce death or HF hospitalization
Authors: Dominic L. Raco
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubDecember 2022In ischemic left ventricular systolic dysfunction, adding PCI to medical therapy did not reduce death or HF hospitalizationDominic L. Raco, MDDominic L. Raco, MDMcMaster University, Hamilton, Ontario, Canada (D.L.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0100 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPerera D, Clayton T, O’Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387:1351-60. https://pubmed.ncbi.nlm.nih.gov/36027563Clinical Impact RatingsCardiology: References1. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. [PMID: 17387127] Google Scholar2. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395-407. [PMID: 32227755] Google Scholar3. OPCI Journal Club: a conversation with Dr. Margaret McEntegart: “REVIVED-BCIS2 Trial.” 1 Oct 2022. Accessed at https://opci.live/opci-manager/library-individual/4313 on 6 Oct 2022. Google Scholar4. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-20. [PMID: 27040723] Google Scholar Author, Article, and Disclosure InformationAffiliations: McMaster University, Hamilton, Ontario, Canada (D.L.R.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0100.This article was published at Annals.org on 6 December 2022.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics December 2022Volume 175, Issue 12Page: JC135KeywordsHealth careHeart failureHospitalizationsIschemiaLeft ventricular ejection fractionLesionsPercutaneous coronary interventionResearch assessmentRevascularization ePublished: 6 December 2022 Issue Published: December 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Maldevelopment of the Immature Pulmonary Vasculature and Prolonged Patency of the Ductus Arteriosus: Association or Cause?
Authors: Patrick J. McNamara, Satyan Lakshminrusimha
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Maldevelopment of the Immature Pulmonary Vasculature and Prolonged Patency of the Ductus Arteriosus – Association or Cause?." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
Authors: Romina Royo, Laura Magnano, Julio Delgado, Sara Ruiz-Gil, Josep Ll. Gelpí, Holger Heyn, Malcom A. Taylor, Tatjana Stankovic, Xose S. Puente, Ferran Nadeu, Elías Campo
Journal: Blood Cancer Journal (2022)

2-3 cm) and splenomegaly of 4 cm below the costal margin.
Amyloid‐Based Albumin Hydrogels
Authors: Carolina Diaz, Dimitris Missirlis
Journal: Advanced Healthcare Materials (2022)

Abstract Amyloid fibrils may serve as building blocks for the preparation of novel hydrogel materials from abundant, low‐cost, and biocompatible polypeptides. This work presents the formation of physically cross‐linked, self‐healing hydrogels based on bovine serum albumin at room temperature through a straightforward disulfide reduction step induced by tris (2‐carboxyethyl) phosphine hydrochloride. The structure and surface charge of the amyloid‐like fibrils is determined by the pH of the solution during self‐assembly, giving rise to hydrogels with distinct physicochemical properties. The hydrogel surface can be readily functionalized with the extracellular matrix protein fibronectin and supports cell adhesion, spreading, and long‐term culture. This study offers a simple, versatile, and inexpensive method to prepare amyloid‐based albumin hydrogels with potential applications in the biomedical field.
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d
Authors: Chirag Bavishi
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubDecember 2022In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 dChirag Bavishi, MD, MPHChirag Bavishi, MD, MPHUniversity of Missouri, Columbia, Missouri, USA (C.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0095 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95. https://pubmed.ncbi.nlm.nih.gov/36027559Clinical Impact RatingsHospitalists: Cardiology: Geriatrics: Author, Article, and Disclosure InformationAffiliations: University of Missouri, Columbia, Missouri, USA (C.B.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0095.This article was published at Annals.org on 6 December 2022.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics December 2022Volume 175, Issue 12Page: JC136KeywordsDiureticsEstimated glomerular filtration rateHeart failureN terminal pro brain natriuretic peptidesRenal analysisRisk ratioSafetySaltsSystolic pressure ePublished: 6 December 2022 Issue Published: December 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005–18: a population-based study
Authors: Xue Cao, Zhenping Zhao, Yuting Kang, Yixin Tian, Yuxin Song, Limin Wang, Linfeng Zhang, Xin Wang, Zuo Chen, Congyi Zheng, Lu Tian, Peng Yin, Yuehui Fang, Mei Zhang, Yuna He, Zugui Zhang, William S Weintraub, Maigeng Zhou, Zengwu Wang
Journal: The Lancet Public Health (2022)
Epidermal Cyst Mimicking Thyroid Cancer Metastasis
Authors: Lingling Luo, Junyong Xia, Qianyu Bian, Linlin Xiao, Xiaobo Yao
Journal: Clinical Nuclear Medicine (2022)

A 26-year-old woman with pulmonary metastasis of thyroid cancer underwent a total thyroidectomy and cervical lymph node dissection followed by 2 courses of 131I therapy. The posttherapeutic whole-body scan after the second dose of 131I therapy showed diffuse tracer uptake in both lungs. Besides this, there is a local abnormal radiotracer uptake in the left axillary region. SPECT/CT images localized this abnormal radioactivity in a subcutaneous, oval-shaped, approximately 2.2-cm slightly hyperdense lesion, which was pathologically confirmed as an epidermal cyst.
Severe exacerbations and mortality in COPD patients: A retrospective analysis of the database of the Hungarian National Health Insurance Fund
Authors: B. Sánta, G. Tomisa, A. Horváth, T. Balázs, L. Németh, G. Gálffy
Journal: Pulmonology (2022)

COPD is one of the most common pulmonary diseases and one of the leading causes of death worldwide. Exacerbations of COPD include acute worsening that could lead to hospitalization and death. In this study, our objective was to investigate the natural course of moderate and severe exacerbations (SAE) and mortality in the Hungarian population in the past decade.A retrospective financial database analysis was performed to examine the risk of additional SAEs and death after the first ever SAE in COPD patients, using the financial database of the Hungarian National Health Insurance Fund (NHIF). Patients were enrolled between 2009.01.01. and 2019.12.31. if they had received at least one inhaled drug (LABA, LAMA, ICS or SABA/SAMA) and had been hospitalized for a COPD exacerbation (ICD-10 code J44).A total of 63,037 patients with COPD were enrolled after their first SAE. Of them, 27,095 patients suffered at least one subsequent SAE, and 32,120 patients died during the 10-year follow-up. The median survival was 4.7 years. The risk of subsequent hospitalizations increased significantly after each SAE, with hazard ratios ranging from 1.65 to 5.01. The risk for mortality was increased after each SAE, but did not increase further with the number of SAEs. Moreover, the risk for subsequent SAE and death increased with moderate exacerbations; however, this risk did not increase further with each event.Despite a relevant improvement in COPD treatment, the natural course of exacerbations remained unchanged. This result highlights the importance of preventing exacerbations and the need for more research to better predict them.
68Ga-DOTATATE PET/CT of ACTH-Independent Cushing Syndrome Due to Ectopic Adrenocortical Adenoma
Authors: Yuanyuan Jiang, Qingxing Liu, Zhaohui Zhu
Journal: Clinical Nuclear Medicine (2022)

Abstract Adrenocorticotropic hormone–independent Cushing syndrome due to ectopic adrenocortical adenoma is a very rare entity. We herein present a case of a 57-year-old woman who was referred to our hospital with persistent Cushing syndrome after undergoing unnecessary laparoscopic left adrenalectomy. 68 Ga-DOTATATE PET/CT revealed increased uptake in the nodule in the right hilum, which was histologically confirmed to be ectopic adrenocortical adenoma. Removal of the tumor was followed by the disappearance of clinical symptoms of Cushing syndrome. In this case, 68 Ga-DOTATATE PET/CT contributed to the diagnosis of ectopic adrenocortical adenoma.
In the general population, salt substitutes vs. regular salt reduce BP levels, CV outcomes, and mortality
Authors: James Brophy
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubDecember 2022In the general population, salt substitutes vs. regular salt reduce BP levels, CV outcomes, and mortalityJames Brophy, MD, PhDJames Brophy, MD, PhDMcGill University, Montreal, Quebec, Canada (J.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0091 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationYin X, Rodgers A, Perkovic A, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022;108:1608-15. https://pubmed.ncbi.nlm.nih.gov/35945000Clinical Impact RatingsGIM/FP/GP: Cardiology: References1. Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385:1067-77. [PMID: 34459569] Google Scholar2. Chang HY, Hu YW, Yue CS, et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr. 2006;83:1289-96. [PMID: 16762939] Google Scholar3. American Heart Association. Sodium sources: Where does all that sodium come from? Last reviewed 23 May 2018. Accessed at www.heart.org/en/healthy-living/healthy-eating/eat-smart/sodium/sodium-sources on 14 Sep 2022. Google Scholar4. Lin JS, O’Connor EA, Evans CV, et al. Behavioral counseling to promote a healthy lifestyle for cardiovascular disease prevention in persons with cardiovascular risk factors: an updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2014. Report No. 13-05179-EF-1. [PMID: 25232633] Google Scholar Author, Article, and Disclosure InformationAffiliations: McGill University, Montreal, Quebec, Canada (J.B.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0091.This article was published at Annals.org on 6 December 2022.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics December 2022Volume 175, Issue 12Page: JC139KeywordsBlood pressureClinical trialsHypertensionMortalityPopulation statisticsRisk ratioSaltsStrokeSystematic reviewsSystolic pressure ePublished: 6 December 2022 Issue Published: December 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Implementation of an Online Reporting System to Identify Unprofessional Behaviors and Mistreatment Directed at Trainees at an Academic Medical Center
Authors: I. Michael Leitman, David Muller, Sophie Miller, Basil G. Hanss, Thomas F. Catron, William O. Cooper, Marta Filizola
Journal: JAMA Network Open (2022)

Unprofessional behaviors and mistreatment directed at trainees continue to challenge the learning environment. Academic medical institutions should encourage reports of inappropriate behavior and address such reports directly to create a safe learning environment.
Process of Hard Palate Osteonecrosis Demonstrated on Serial 18F-FDG PET/CT Scans
Authors: Le Song, Hui Li, Weifang Zhang
Journal: Clinical Nuclear Medicine (2022)

Abstract Osteonecrosis of the hard palate is rare. Here, we demonstrated the dynamic metabolic and structural changes during the process of osteonecrosis of the hard palate by serial 18 F-FDG PET/CT scans in a patient with nasal NK/T-cell lymphoma. On the baseline scan, increased FDG uptake in the periphery of the hard palate could be observed. On the following scans after treatment, a focal metabolic defect on the hard palate with no structural changes and with bone sequestration and perforation have been observed successively. Our case indicates that the metabolic defect on 18 F-FDG PET/CT may be an early sign of osteonecrosis.
Yield of Cardiac Magnetic Resonance Imaging in a Preparticipation Cohort of Young Asian Males With T Wave Inversion
Authors: Nishanth Thiagarajan, Wilbert H.H. Ho, Daniel Y.Z. Lim, Wesley T.W. Loo, Goy Shen, Vahul Sundar, Huai Yang Lim, Lian Kiat Lim, Terrance S.J. Chua, Paul C.Y. Lim, Hak Chiaw Tang, Choong Hou Koh, Tee Joo Yeo, Daniel T.T. Chong
Journal: Circulation (2022)
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia
Authors: Ana Margarida Pinto, Rinie Geenen, Tor D. Wager, Mark A. Lumley, Winfried Häuser, Eva Kosek, Jacob N. Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J. Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip J. Mease, Filipe Palavra, Jamie L. Rhudy, Lucina Q. Uddin, Paula Castilho, Johannes W. G. Jacobs, José A. P. da Silva
Journal: Nature Reviews Rheumatology (2022)
In monkeypox, risk for some symptoms was greater in MSM with vs. without receptive anal contact
Authors: Muhddesa Lakhana, Moshe Fenster, Aaron E. Glatt
Journal: Annals of Internal Medicine (2022)

Source Citation Tarín-Vicente EJ, Alemany A, Agud-Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400:661-9. 35952705
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Authors: Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu
Journal: Journal for ImmunoTherapy of Cancer (2022)

Agents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC). However, the response rate of anti-PD-1/PD-L1 is still unsatisfactory, partly due to immunosuppressive factors such as transforming growth factor-beta (TGF-β). In our previous pilot study, the bispecific antibody targeting TGF-β and murine PD-L1 (termed YM101) showed potent antitumor effect. In this work, we constructed a bispecific antibody targeting TGF-β and human PD-L1 (termed BiTP) and explored the antitumor effect of BiTP in TNBC.BiTP was developed using Check-BODYTM bispecific platform. The binding affinity of BiTP was measured by surface plasmon resonance, ELISA, and flow cytometry. The bioactivity was assessed by Smad and NFAT luciferase reporter assays, immunofluorescence, western blotting, and superantigen stimulation assays. The antitumor activity of BiTP was explored in humanized epithelial-mesenchymal transition-6-hPDL1 and 4T1-hPDL1 murine TNBC models. Immunohistochemical staining, flow cytometry, and bulk RNA-seq were used to investigate the effect of BiTP on immune cell infiltration.BiTP exhibited high binding affinity to dual targets. In vitro experiments verified that BiTP effectively counteracted TGF-β-Smad and PD-L1-PD-1-NFAT signaling. In vivo animal experiments demonstrated that BiTP had superior antitumor activity relative to anti-PD-L1 and anti-TGF-β monotherapy. Mechanistically, BiTP decreased collagen deposition, enhanced CD8+ T cell penetration, and increased tumor-infiltrating lymphocytes. This improved tumor microenvironment contributed to the potent antitumor activity of BiTP.BiTP retains parent antibodies' binding affinity and bioactivity, with superior antitumor activity to parent antibodies in TNBC. Our data suggest that BiTP might be a promising agent for TNBC treatment.
Comparison between obese and non-obese nonalcoholic fatty liver disease
Authors: Wah-Kheong Chan
Journal: Clinical and Molecular Hepatology (2022)

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.
68Ga-FAPI PET/CT in a Patient With Statin-Induced Rhabdomyolysis
Authors: Ya Liu, Chunmei Guo, Liming Chen, Zhanwen Huang
Journal: Clinical Nuclear Medicine (2022)

Abstract Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of muscle cell contents into blood circulation. There is ample clinical evidence that it is one of the adverse effects of statins. 68 Ga-FAPI PET/CT was performed on a 78-year-old man with newly diagnosed with mediastinal tumor and statin-induced rhabdomyolysis. 68 Ga-FAPI PET/CT showed symmetrical and diffuse increased FAPI uptake in whole-body muscles. Our case indicated that 68 Ga-FAPI PET/CT might be valuable in the evaluation of patients with rhabdomyolysis.
In adults, risk for infective endocarditis varied for invasive dental procedures and by antibiotic prophylaxis
Authors: Henry S. Sacks
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubDecember 2022In adults, risk for infective endocarditis varied for invasive dental procedures and by antibiotic prophylaxisHenry S. Sacks, PhD, MDHenry S. Sacks, PhD, MDIcahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0097 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationThornhill MH, Gibson TB, Yoon F, et al. Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. J Am Coll Cardiol. 2022;80:1029-41. https://pubmed.ncbi.nlm.nih.gov/35987887Clinical Impact RatingsCardiology: Infectious Disease: References1. Rutherford SJ, Glenny AM, Roberts G, et al. Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures. Cochrane Database Syst Rev. 2022;5:CD003813.[PMID: 35536541] Google Scholar2. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation. 2007;116:1736-54. [PMID: 17446442] Google Scholar3. Fiore DC, Fettic LP, Wright SD, et al. Antibiotic overprescribing: still a major concern. J Fam Pract. 2017;66:730-6. [PMID: 29202142] Google Scholar4. American Heart Association. Prevention of infective endocarditis wallet card. Accessed at www.heart.org/-/media/Files/Health-Topics/Infective-Endocarditis/Infective-Endocarditis-Wallet-Card.pdf on 28 Sep 2022. Google Scholar Author, Article, and Disclosure InformationAffiliations: Icahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0097.This article was published at Annals.org on 6 December 2022.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics December 2022Volume 175, Issue 12Page: JC143KeywordsAntibiotic prophylaxisAntibiotic resistanceCongenital heart diseaseEndocarditisHeartHospitalizationsInformation storage and retrievalOdds ratioRandomized trials ePublished: 6 December 2022 Issue Published: December 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Interaction between sarcopenia and nonalcoholic fatty liver disease
Authors: Sae Kyung Joo, Won Kim
Journal: Clinical and Molecular Hepatology (2022)

Sarcopenia and nonalcoholic fatty liver disease (NAFLD) are common health problems related to aging. Despite the differences in their diagnostic methods, several cross-sectional and longitudinal studies have revealed the close link between sarcopenia and NAFLD. Sarcopenia and NAFLD are linked by several shared pathogenetic mechanisms, including insulin resistance, hormonal imbalance, systemic inflammation, myostatin and adiponectin dysregulation, nutritional deficiencies, and physical inactivity, thus implicating a bidirectional relationship between sarcopenia and NAFLD. However, there is not sufficient data to support a direct causal relationship between sarcopenia and NAFLD. Moreover, it is currently difficult to conclude whether sarcopenia is a risk factor for nonalcoholic steatohepatitis (NASH) or is a consequence of NASH. Therefore, this review intends to touch on the shared common mechanisms and the bidirectional relationship between sarcopenia and NAFLD.